-+ 0.00%
-+ 0.00%
-+ 0.00%

Rhythm Pharmaceuticals' Setmelanotide Sustains 18.8% Mean BMI Reduction at Two Years in Phase 3 Trial

PUBT·11/16/2026 21:01:07
Listen to the news
Rhythm Pharmaceuticals' Setmelanotide Sustains 18.8% Mean BMI Reduction at Two Years in Phase 3 Trial
  • Rhythm Pharmaceuticals presented two-year results from the Phase 3 TRANSCEND trial of setmelanotide in acquired hypothalamic obesity at ObesityWeek 2026.
  • Continuous treatment sustained reductions in body mass index; patients who switched from placebo also showed reductions at two years.
  • The safety profile was generally consistent with previous trials in acquired hypothalamic obesity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611161600PRIMZONEFULLFEED9877631) on November 16, 2026, and is solely responsible for the information contained therein.